In late 2022, the Council of the European Union updated its recommendations on cancer screening to include prostate cancer as a target, calling on member states to initiate organized pilot programs for PSA-based screening in conjunction with MRI as a second-line test [8]. This evidence concerns the gene KLK3 and prostate carcinoma.